-
Patent Agency Ranking
1.发明申请ANTICANCER PRODRUGS ACTIVATED BY RADIATION OR ULTRAVIOLET TREATMENT AND USE THEREOF 审中-公开通过辐射或超紫外线治疗及其使用而起作用的抗癌药物公开(公告)号：US20160184430A1
公开(公告)日：2016-06-30
申请号：US14974490
申请日：2015-12-18
Applicant: Korea Institute of Science and Technology
Inventor： Ju-Hee Ryu , Kwang-Meyung Kim , Ick-Chan Kwon , Kui-Won Choi , Sang-Yoon Kim , Beom-Suk Lee , Dae-Yoon Chi , Hee-Seup Kil , Hyun-Ju Sung
CPC classification number: A61K41/0042 , A61K31/704 , A61K38/00 , A61K47/64 , A61N5/062 , A61N5/1001
Abstract: The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid and base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.
Abstract translation: 本发明涉及一种由乙酰基-SEQ ID NO.1-接头 - 抗癌药物的肽组成的抗癌药物。 抗癌前药有效地提供了在酸和碱中不稳定的抗癌药物，例如以前药形式的多柔比星。 因此，当施用于体内时，抗癌前药以无毒无活性形式存在，但在施用于体内后，通过辐射或UV治疗活化的半胱天冬酶存在下，有效地将抗癌药物作为活性成分释放到目标区域。 因此，抗癌药物对癌细胞具有选择性的抗癌作用，从而最大化治疗效果并使化疗的副作用最小化。
-
公开(公告)号：US20170183416A1
公开(公告)日：2017-06-29
申请号：US15363103
申请日：2016-11-29
Applicant: SEOUL NATIONAL UNIVERSITY , UNIVERSITY OF ULSAN , KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , PHARSOGEN
Inventor： Youngro Byun , In San Kim , Ahmed Al-Hilal Taslim , Sang-Yoon Kim , Ye Ji Jang
IPC: C07K16/28 , G01N33/574 , G01N33/68 , A61K31/727
CPC classification number: C07K16/2872 , A61K31/727 , A61K39/3955 , A61K47/554 , C07K14/705 , C07K16/18 , C07K16/28 , C07K2317/14 , C07K2317/73 , C07K2317/76 , C12N15/113 , C12N2310/11 , C12N2310/3515 , G01N33/57492 , G01N33/6893 , G01N2333/705
Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
-
3.发明授权Anticancer prodrugs activated by radiation or ultraviolet treatment and use thereof 有权通过辐射或紫外线处理活化的抗癌前药及其用途公开(公告)号：US09408911B2
公开(公告)日：2016-08-09
申请号：US14974490
申请日：2015-12-18
Applicant: Korea Institute of Science and Technology
Inventor： Ju-Hee Ryu , Kwang-Meyung Kim , Ick-Chan Kwon , Kui-Won Choi , Sang-Yoon Kim , Beom-Suk Lee , Dae-Yoon Chi , Hee-Seup Kil , Hyun-Ju Sung
CPC classification number: A61K41/0042 , A61K31/704 , A61K38/00 , A61K47/64 , A61N5/062 , A61N5/1001
Abstract: The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid and base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.
Abstract translation: 本发明涉及一种由乙酰基-SEQ ID NO.1-接头 - 抗癌药物的肽组成的抗癌药物。 抗癌前药有效地提供了在酸和碱中不稳定的抗癌药物，例如以前药形式的多柔比星。 因此，当施用于体内时，抗癌前药以无毒无活性形式存在，但在施用于体内后，通过辐射或UV治疗活化的半胱天冬酶存在下，有效地将抗癌药物作为活性成分释放到目标区域。 因此，抗癌药物对癌细胞具有选择性的抗癌作用，从而最大化治疗效果并使化疗的副作用最小化。
-
公开(公告)号：US10202459B2
公开(公告)日：2019-02-12
申请号：US15363103
申请日：2016-11-29
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , UNIVERSITY OF ULSAN , KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , PHAROSGEN
Inventor： Youngro Byun , In San Kim , Ahmed Al-Hilal Taslim , Sang-Yoon Kim , Ye Ji Jang
IPC: A61K39/395 , C07K16/18 , C07K16/28 , A61K31/727 , G01N33/574 , G01N33/68 , C07K14/705 , C12N15/113 , A61K47/54
Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
-
公开(公告)号：US20170260278A1
公开(公告)日：2017-09-14
申请号：US15450272
申请日：2017-03-06
Applicant: SEOUL NATIONAL UNIVERSITY , UNIVERSITY OF ULSAN , KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , PHAROSGEN
Inventor： Youngro Byun , In San Kim , Ahmed Al-Hilal Taslim , Sang-Yoon Kim , Ye Ji Jang
IPC: C07K16/28
CPC classification number: C07K16/2872 , A01K2217/075 , A01K2227/105 , A61K47/55 , A61K47/554 , A61K47/61 , A61K2039/505 , A61P35/00 , C07K16/30 , C07K2317/70 , C07K2317/73 , C07K2317/76 , C12N15/113 , C12N2310/11 , C12N2310/3515 , C12Q1/68 , G01N33/57492 , G01N33/6893 , G01N2333/705
Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
-
-
-
-
Search Results
5
records
(took 0.017 seconds)
